|
... managed by dose reduction and/or interruption of therapy. INCB18424: Additional Myeloproliferative Diseases: Polycythemia Vera (PV) and Essential Thrombocythemia (ET) -- Ongoing enrollment and site initiation of an open-label multiple-dose Phase II ...
|
|
... causes of elevated hematocrit are lung disease, certain tumors, a disorder of the bone marrow known as polycythemia rubra vera, and abuse of the drug erythropoietin (Epogen) by athletes for blood doping purposes. Reference: Harrison's Principles of ...
|